文章：

Treatment Sequencing in Chronic Lymphocytic Leukemia in 2024: Where We Are and Where We Are Headed

原文发布日期：25 May 2024

DOI: 10.3390/cancers16112011

类型: Article

开放获取: 是

英文摘要：

As treatments with BTK inhibitors and BCL2 inhibitors have replaced the use of chemoimmunotherapy in CLL in both first-line and relapsed patients, it becomes critical to rationalize their use and exploit the full potential of each drug. Despite their proven, robust, and manifest efficacy, BTKis and BCL2is fail to provide long-term disease control in some categories of patients, and to date this is an unmet clinical need that is critical to recognize and address. Ongoing clinical trials are evaluating new treatment algorithms and new molecules to progressively thin this population. In this review for each category of patients we explicate the different possible patterns of treatment sequencing based on currently available evidence, starting from the frontline to currently ongoing trials, in order to optimize therapies as much as possible.

摘要翻译： 

随着BTK抑制剂和BCL2抑制剂在慢性淋巴细胞白血病（CLL）的一线及复发患者治疗中逐渐取代化学免疫疗法，如何合理应用这些药物并充分发挥其治疗潜力显得至关重要。尽管BTK抑制剂和BCL2抑制剂已被证实具有显著且稳定的疗效，但在部分患者群体中仍无法实现长期疾病控制，这一尚未满足的临床需求亟待识别与解决。当前正在进行的临床试验正通过探索新的治疗方案及新型分子药物，逐步缩小这类患者的规模。本综述针对不同患者群体，基于现有证据从一线治疗到当前进行中的试验，系统阐述可能的治疗序贯策略，以期实现治疗方案的优化。

原文链接：

Treatment Sequencing in Chronic Lymphocytic Leukemia in 2024: Where We Are and Where We Are Headed